Abstract: 【Abstract】 Objective To evaluate the long-term clinical effect of combined therapy with peritoneal dialysis and hemodialysis (PHD) in the treatment of patients with end-stage renal disease (ESRD). Methods We summarized the effect of PHD in 3 ESRD cases and reviewed the related literature. Results The 3 male ESRD cases were 34-54 years old, and were undergone PHD for 1-4 years. The primary disease was chronic glomerulonephritis in 2 cases, diabetic nephropathy in one case. After PHD treatment, clinical status improved. In case 1, weekly urea Kt/V increased from 1.46 to 1.90, weekly creatinine clearance (WCC) from 36.52 to 60.72 L/1.73 m2, plasma albumin from 3.30 mg/dl to 3.60 mg/dl, and hemoglobin from 8.1 g/dl to 11.0 g/dl. Echocardiography showed the improvement of left ventricular hypertrophy. In case 2, weekly urea Kt/V increased from 1.43 to 1.81, WCC from 35.34 to 55.79 L/1.73 m2, plasma albumin from 3.50 mg/dl to 3.92 mg/dl, and hemoglobin from 9.6 g/dl to 11.6 g/dl. In case 3, weekly urea Kt/V increased from 1.55 to 1.82, WCC from 46.0 to 56.53 L/1.73 m2, plasma albumin from 3.50 mg/dl to 4.02 mg/dl, and hemoglobin from 7.8 g/dl to 9.2 g/dl. Echocardiography showed the improvement of left ventricular hypertrophy. Conclusion PHD can effectively improve the clinical symptoms and dialysis adequacy in ESRD patients. It may be used as a supplementary alternative of renal replacement therapy in clinical practice.

Key words: End-stage renal disease, combined therapy with Peritoneal Dialysis and Hemodialysis, long-term clinical effect